Canada forced to honour Bayer's patent on ciprofloxacinBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7319.956/b (Published 27 October 2001) Cite this as: BMJ 2001;323:956
- David Spurgeon
In an embarrassing mix-up, Canada's federal government will pay twice for a supply of the antibiotic ciprofloxacin (marketed as Cipro) that it ordered to protect Canadians in case they are faced with an outbreak of anthrax, as has happened in the United States.
The federal health department broke its own drug patent rules when it ordered the drug from a generic drug manufacturer, Apotex. The patent, held by Bayer AG, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial